- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | H.C. Wainwright hebt Kursziel für Climb Bio wegen Budoprutug-Fortschritten auf 11 US-Dollar an | 3 | Investing.com Deutsch | ||
| CLIMB BIO Aktie jetzt für 0€ handeln | |||||
| Do | H.C. Wainwright raises Climb Bio stock price target to $11 on budoprutug progress | 2 | Investing.com | ||
| 11.12. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.11. | Climb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 5 | GlobeNewswire (USA) | ||
| 06.11. | Climb Bio, Inc.: Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates | 121 | GlobeNewswire (Europe) | PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical... ► Artikel lesen | |
| 06.11. | Climb Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11. | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10. | Climb Bio, Inc.: Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy | 244 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced... ► Artikel lesen | |
| 17.10. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | Climb Bio, Inc.: Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 | 1 | GlobeNewswire (USA) | ||
| 16.10. | Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity | 1 | Benzinga.com | ||
| 16.10. | William Blair initiates coverage on Climb Bio stock with Outperform rating | 1 | Investing.com | ||
| 01.10. | Climb Bio beruft Susan Altschuller zur neuen Finanzvorständin | 3 | Investing.com Deutsch | ||
| 01.10. | Climb Bio taps Susan Altschuller as CFO | 1 | Seeking Alpha | ||
| 01.10. | Climb Bio Appoints Susan Altschuller As New CFO | 2 | RTTNews | ||
| 01.10. | Climb Bio, Inc.: Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer | 110 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced... ► Artikel lesen | |
| 30.09. | BTIG hebt Kursziel für Climb Bio auf 8 US-Dollar an - Potenzial von CLYM116 im Fokus | 1 | Investing.com Deutsch | ||
| 30.09. | Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential | 1 | Investing.com | ||
| 29.09. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | Climb Bio reports promising preclinical data for IgA nephropathy drug | 1 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,75 | +0,89 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| EVOTEC | 5,170 | +0,51 % | Sonntagsausblick: Evotec-Aktie vor spannender Handelswoche - Experten sind sich uneinig! | ||
| MEDIGENE | 0,022 | -13,85 % | MEDIGENE AG stürzt ab - das ist erst der Anfang! | ||
| CUREVAC | 3,498 | -1,96 % | BioNTech SE: BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld | BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen... ► Artikel lesen | |
| MODERNA | 28,465 | -1,32 % | Moderna, Inc.: CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate | Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensurePartnership strengthens global preparedness against a significant pandemic threatIf... ► Artikel lesen | |
| VALNEVA | 3,526 | +0,40 % | Wochenend-Update: Valneva-Aktie im Fokus - was Anleger jetzt wissen müssen! | ||
| NOVAVAX | 5,754 | +1,09 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| ILLUMINA | 114,54 | -0,47 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 655,00 | -0,12 % | Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement | ||
| INOVIO PHARMACEUTICALS | 2,020 | +4,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,935 | -0,35 % | Viking Therapeutics, Inc. (VKTX): A Bull Case Theory | ||
| BAVARIAN NORDIC | 25,440 | +0,55 % | Bavarian Nordic A/S: Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees | COPENHAGEN, Denmark, December 18, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,864 | -0,41 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,439 | +7,60 % | Kursexplosion nach News? NurExone lässt die Bombe platzen!! | ||
| MICROBOT MEDICAL | 1,810 | +1,12 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen |
Das Unternehmen CLIMB BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,28 % bei einem Aktienkurs von 4,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CLIMB BIO INC finden Sie auf Wallstreet Online.